Neola Medical CEO Hanna Sjöström recently presented the company at BioStock Life Science Summit 2026, highlighting the progress made during the year and the company’s path toward the next phase of U.S. development.
In the presentation, Hanna Sjöström outlines Neola Medical’s focus on addressing an important unmet need in neonatal intensive care with continuous, non-invasive lung monitoring. The presentation also covers the company’s recent clinical progress, the sharpened focus on detection of life-threatening lung complications, the FDA Breakthrough Device Designation, the U.S. market opportunity and Neola Medical’s recurring revenue model based on the Neola® monitoring system and daily disposable probes. The presentation concludes with the company’s key value drivers and upcoming milestones.
